BioSpace News Archive

AIM ImmunoTech Inc. today announced the first subject has been dosed at Erasmus Medical Center (“Erasmus MC”) in a Phase 1b/2 clinical trial combining AIM’s Ampligen® (rintatolimod) with AstraZeneca’s anti-PD-L1 immune checkpoint inhibitor Imfinzi® (durvalumab) for the treatment of late-stage pancreatic cancer (the “DURIPANC Study”).

Portfolio of early- and late-stage clinical services advances product development for injectables

Atara Biotherapeutics, Inc. today announced its recent submission of an Investigational New Drug (IND) application to the U.S. Food and Drug Administration (FDA) for the use of ATA3219 as a monotherapy for the treatment of systemic lupus erythematosus (SLE) with kidney involvement (lupus nephritis [LN]).

Petros Pharmaceuticals, Inc. announces a new partnership with a leading, multi-billion-dollar AI software provider to adapt its technology for self-screening and other benefits as part of the Company’s ongoing efforts to bring STENDRA over the counter.

Blacksmith Medicines, Inc. and Zoetis announced a collaboration to discover and develop novel antibiotics for animal health.

HistoSonics® announced that the company’s Edison System has been selected to participate in the UK’s newly created Innovative Devices Access Pathway Pilot Program designed to accelerate the development of cost-effective medical devices and their integration into the UK market.

Genmab A/S announced the publication of its Annual Report for 2023.

Medline announced it has expanded its prime vendor agreement with California-based healthcare network PIH Health.

Genmab A/S announced that it is initiating a share buy-back program to honor our commitments under our Restricted Stock Unit program.

Starton Therapeutics Inc. (“Starton” or “the Company”), a clinical-stage biotechnology company focused on transforming standard-of-care therapies with proprietary continuous delivery technology, announced Regional Medical Oncology Center (RMOC) in Wilson, NC as the second site activated in the STAR-LLD Phase 1b clinical trial.